FDA expands use of Simponi to include ulcerative colitis

05/15/2013 | Drug Store News

Johnson & Johnson obtained FDA approval to market Simponi, or golimumab, as a treatment for moderate to severe forms of ulcerative colitis in adults. The drug, a tumor necrosis factor inhibitor previously approved for rheumatoid arthritis, is manufactured by J&J unit Janssen Biotech.

View Full Article in:

Drug Store News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA